EXEL (US)


March 24, 2026

Rx Pricing: MFN “Deals” & Legal Landmines

By John Leppard

Our review of comment submissions for CMS’s most favored nation (MFN) drug pricing model proposals in Medicare Part D (GUARD) and B (GLOBE) leave us with just ~30% odds of their being implemented. The risk…

Read More >>

December 21, 2025

Rx Model Risks: So Much For “Deals”

By John Leppard

CMS’s mandatory Medicare Part D (here) / Part B (here) international drug pricing model proposals released Friday suggest that – besides an ostensible reprieve from as yet unrealized tariffs – recent drug manufacturer “deals” with…

Read More >>